We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

70 hedge funds and large institutions have $103M invested in Protagonist Therapeutics in 2018 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

107% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 15

36% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 14

6% more funds holding

Funds holding: 66 → 70 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.23% less ownership

Funds ownership: 57.79% → 56.56% (-1.2%)

55% less capital invested

Capital invested by funds: $226M → $103M (-$123M)

Holders
70
Holders Change
+4
Holders Change %
+6.06%
% of All Funds
1.6%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
19
Increased
31
Reduced
15
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
+$20.4M
2
BlackRock
BlackRock
New York
+$3.63M
3
American Century Companies
American Century Companies
Missouri
+$2.69M
4
TCM
Tekla Capital Management
Massachusetts
+$2.57M
5
OAM
Oxford Asset Management
United Kingdom
+$2.49M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$19.9M
2
EAM
Eventide Asset Management
Massachusetts
-$5.72M
3
First Manhattan
First Manhattan
New York
-$5.12M
4
DM
Deerfield Management
New York
-$4.68M
5
JP Morgan Chase
JP Morgan Chase
New York
-$3.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$423K +$927K +49,197 New
Two Sigma Advisers
27
Two Sigma Advisers
New York
$405K +$559K +29,700 +171%
FSA
28
Franklin Street Advisors
North Carolina
$401K – – –
BCM
29
Bridgeway Capital Management
Texas
$335K – – –
AIM
30
Alambic Investment Management
California
$324K +$710K +37,700 New
Two Sigma Investments
31
Two Sigma Investments
New York
$282K -$470K -24,976 -43%
Charles Schwab
32
Charles Schwab
California
$278K +$245K +13,015 +67%
Goldman Sachs
33
Goldman Sachs
New York
$267K +$28.4K +1,506 +5%
Morgan Stanley
34
Morgan Stanley
New York
$242K +$11.2K +593 +2%
AA
35
ALPS Advisors
Colorado
$236K +$89.9K +4,774 +21%
TI
36
Trexquant Investment
Connecticut
$193K +$102K +5,400 +32%
TA
37
Teachers Advisors
New York
$185K – – –
ECM
38
Element Capital Management
New York
$175K +$383K +20,346 New
California State Teachers Retirement System (CalSTRS)
39
California State Teachers Retirement System (CalSTRS)
California
$151K -$6.63K -352 -2%
T. Rowe Price Associates
40
T. Rowe Price Associates
Maryland
$142K +$127K +6,722 +68%
Squarepoint
41
Squarepoint
New York
$142K +$311K +16,531 New
Deutsche Bank
42
Deutsche Bank
Germany
$128K -$208K -11,070 -42%
SO
43
STRS Ohio
Ohio
$118K +$215K +11,400 +475%
New York State Common Retirement Fund
44
New York State Common Retirement Fund
New York
$117K +$64K +3,400 +33%
Prudential Financial
45
Prudential Financial
New Jersey
$116K +$256K +13,570 New
DZ Bank
46
DZ Bank
Germany
$113K +$247K +13,100 New
Barclays
47
Barclays
United Kingdom
$102K +$69K +3,661 +45%
Balyasny Asset Management
48
Balyasny Asset Management
Illinois
$102K +$223K +11,864 New
CSS
49
Cubist Systematic Strategies
Connecticut
$100K +$157K +8,327 +255%
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$88K +$194K +10,294 New
1
2
3 4

PTGX Hedge Fund Activity: Q1 2018 in Review

70 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q1 2018, worth a combined $103M — down 55% from $226M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new PTGX positions and 14 closed out — a net gain of 5 holders — while 31 added to existing stakes and 15 trimmed.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $20.4M. The largest seller was Adage Capital Partners, cutting an estimated $19.9M.

  • 70 institutional investors held Protagonist Therapeutics (PTGX) as of Q1 2018, up from 66 in Q4 2017.
  • Funds reported $103M of Protagonist Therapeutics stock for Q1 2018, down 55% quarter-over-quarter.
  • 19 funds opened new Protagonist Therapeutics positions in Q1 2018 and 14 closed out, a net change of +5 holders.
  • The largest Protagonist Therapeutics buyer in Q1 2018 was EcoR1 Capital, an estimated $20.4M added.
  • The largest Protagonist Therapeutics seller in Q1 2018 was Adage Capital Partners, an estimated $19.9M sold.

Based on aggregated 13F filings for Q1 2018.